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Survival depends on an organism’s ability to sense nutrient status and accordingly
regulate intake and energy expenditure behaviors. Uncoupling of energy sensing and
behavior, however, underlies energy balance disorders such as anorexia or obesity. The
hypothalamus regulates energy balance, and in particular the lateral hypothalamic area
(LHA) is poised to coordinate peripheral cues of energy status and behaviors that impact
weight, such as drinking, locomotor behavior, arousal/sleep and autonomic output. There
are several populations of LHA neurons that are defined by their neuropeptide content
and contribute to energy balance. LHA neurons that express the neuropeptides melanin-
concentrating hormone (MCH) or orexins/hypocretins (OX) are best characterized and
these neurons play important roles in regulating ingestion, arousal, locomotor behavior
and autonomic function via distinct neuronal circuits. Recently, another population of
LHA neurons containing the neuropeptide Neurotensin (Nts) has been implicated in
coordinating anorectic stimuli and behavior to regulate hydration and energy balance.
Understanding the specific roles of MCH, OX and Nts neurons in harmonizing energy
sensing and behavior thus has the potential to inform pharmacological strategies to modify
behaviors and treat energy balance disorders.
Keywords: lateral hypothalamic area, orexin, melanin concentrating hormone, neurotensin, dopamine, feeding,
obesity
THE PERIPHERY AND THE BRAIN ACT IN CONCERT TO
REGULATE ENERGY BALANCE
Food and water are essential for survival, and organisms have
developed physiological systems to ensure that the body maintains
sufficient stores of these resources (Sternson, 2013). Such
systems must synthesize two crucial processes: energy sensing
(to determine the resource needs of the body) and appropriate
output behaviors that are organized by the brain (to resolve
bodily need). For example, resource deficits such as fasting or
dehydration increase the motivation to find and ingest food and
water, respectively. Resource excess is also coordinated with an
appropriate behavioral response: stomach fullness or increased
energy reserves (e.g., body fat) cue the cessation of feeding
while also promoting physical activity and fat burning to resolve
energy excess (Nogueiras et al., 2008; Myers et al., 2009). At
their essence, such physiologic “drive” systems thus match bodily
need and behavior to ensure survival. These systems must also
be dynamic, since bodily resource needs fluctuate considerably
each day (from periods of repletion to deficit and back again),
and must continually survey the energy and hydration status
of the body to detect and resolve any imbalance. Furthermore,
physiologic systems that modulate drive to drink, eat and move
inherently regulate energy balance- the caloric intake and energy
expended that together determine the weight of the organism.
Extreme deficits in energy intake impair survival, while excesses in
energy can promote metabolic disease and co-morbidities. Thus,
survival and energy balance are irrevocably linked, and rely on
constant, dynamic communication between the periphery and the
brain.
How then does the body convey messages that can be “read”
by the brain, and how does the brain interpret these into
behaviors to correct energy imbalance? A major step forward
in understanding this process was the discovery of circulating
hormones that communicate energy status from the periphery to
the brain, and how their absence promotes disease. Insulin was
the first hormonal body-to-brain regulator to be characterized in
control of energy balance (Chen et al., 1975). Insulin is secreted
by pancreatic β-cells and is transported from plasma into the
brain (Schwartz et al., 1991), where it acts to suppress feeding,
hepatic glucose production and to promote weight loss (Woods
et al., 1979; Obici et al., 2002). Loss of insulin signaling in
the brain, however, promotes overeating, insulin resistance and
obesity (Bruning et al., 2000). Another important hormone in
body-to-brain signaling is leptin, which is produced in adipose
tissue and acts via neurons in the brain that express the long
form of the leptin receptor (LepRb) to suppress feeding and
promote energy expenditure (Halaas et al., 1995; Pelleymounter
et al., 1995; Chua et al., 1996; Cohen et al., 2001). Loss of
either peripheral leptin production or central LepRb expression
promotes overeating, decreases energy output and leads to severe
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obesity in rodents (Halaas et al., 1995; Pelleymounter et al.,
1995; Chua et al., 1996) and humans (Montague et al., 1997;
Farooqi et al., 1999), revealing the crucial role of this
periphery/brain regulatory system. The hormone ghrelin also
mediates powerful control of energy balance via regulation in
the brain. Ghrelin is produced by the stomach during periods of
energy deficit and acts via brain neurons expressing the growth
hormone secretagogue receptor (GHSR) to stimulate feeding
(Nakazato et al., 2001; Zigman et al., 2005). Increased ghrelin
action via GHSR promotes over-feeding and potentiates weight
gain (Tschop et al., 2000). These examples demonstrate that
peripheral cues access the brain to either promote or inhibit
feeding behaviors, and thus regulate energy balance.
Normal energy balance relies on the appropriate synergism
of peripheral cues and behavior, but uncoupling these deranges
energy balance. Indeed, individuals with anorexia nervosa self-
restrict their feeding despite having intact cues signaling energy
need (Kaye et al., 2013). Similarly, tastiness can trump satiation:
few among us are invulnerable to the attractive sight and
smell of a dessert, despite having just consumed an ample
meal and being energy replete. As such, normal weight and
obese individuals may over consume palatable, calorie-dense
foods despite the presence of energy excess signals that should
inhibit intake (Berthoud, 2012). Thus, eating disorders or
obesity occur when the need to eat no longer matches the desire
to eat (Berridge et al., 2010), incurring serious health tolls
including increased mortality. Yet despite the increasing severity
of anorexia in youth (Smink et al., 2012) and the obesity
pandemic (Swinburn et al., 2011; Flegal et al., 2012), there remain
limited pharmacologic strategies to treat energy imbalance (Bailey
et al., 2014; Bray and Ryan, 2014). Modifying diet and exercise
remains the gold standard treatment for disordered energy
balance, but these lifestyle changes are difficult to maintain
long term, yield modest improvements in body weight and
prove largely ineffective at improving functional outcomes and
life expectancy (Hart et al., 2013; Look et al., 2013; Jensen
et al., 2014). Surgical interventions such as gastric banding or
gastric bypass are effective in promoting weight loss in obese
individuals, but these procedures are highly invasive and many
individuals regain weight in subsequent years (Meguid et al.,
2008; Dayyeh et al., 2010). It is therefore imperative to identify
strategies to restore normal energy balance function to treat
the millions of individuals suffering from obesity and eating
disorders. Identifying the brain mechanisms that coordinate
energy cues and appropriate behavioral response will suggest
tractable pharmacological pathways to treat feeding and energy
balance disorders.
While many areas of the brain contribute importantly to the
regulation of feeding and metabolism, this review will focus on
the role of the lateral hypothalamic area (LHA) in controlling
energy balance for three reasons: (1) The LHA modifies intake
of natural and pharmacologic rewards and physical activity, and
such function via the LHA is required for survival, (2) The LHA
receives circulating energy balance cues and projects to brain
regions that regulate motivated behaviors, (3) Distinct neuronal
populations within the LHA are “tuned” to specific energy cues
(such as ghrelin or leptin) and induce cue-appropriate behavioral
responses. Thus, understanding the precise neurochemistry,
connectivity and function of the LHA neuronal subpopulations
will suggest mechanisms by which to suppress or enhance feeding,
drinking and energy expenditure as required to restore energy
balance. Modifying action via the LHA therefore has potential to
improve a spectrum of health problems.
THE LATERAL HYPOTHALAMIC AREA (LHA) IS A CRUCIAL
REGULATOR OF ENERGY BALANCE
The hypothalamus as a whole has long been recognized to
modulate body weight, water balance, body temperature and
the sympathetic nervous system (Ranson, 1937). Hetherington
and Ranson were the first to imply that each sub-region of
the hypothalamus controls specific facets of energy balance,
demonstrating that selective lesion of the ventromedial nucleus
of the hypothalamus (VMH) caused profound overeating and
obesity. The VMH was hence deemed an essential “satiety center”
of the brain (Hetherington and Ranson, 1939, 1940) and inspired
many labs to study “hypothalamic obesity” caused by VMH
lesions. It was in this context that Bal K. Anand (while working
at Yale with Brobeck) was using stereotaxic techniques to lesion
the VMH of rats and, by his account, “. . .was much disconcerted
to find that my rats immediately after such lesions completely
stopped eating and would die of starvation”. This phenotype was
completely opposite of the hyperphagia and obesity expected due
to lesion of the VMH (Anand, 1980). As it turned out, Anand
and Brobeck had made a (fortuitous) targeting error, missing
the VMH, but instead ablating the LHA in their experimental
rats. The resulting LHA-lesioned rats had the ability to move,
eat and drink, but lost all motivation to do so: as a result they
all died of self-inflicted starvation and dehydration (Anand and
Brobeck, 1951a,b; Morrison et al., 1958). By contrast, electrical
stimulation of the LHA promotes feeding and drinking behaviors,
as well as increasing physical activity (Delgado and Anand, 1953;
Mogenson and Morgan, 1967; Mogenson and Stevenson, 1967).
Collectively, these seminal loss and gain of function experiments
led to the initial designation of the LHA as a “feeding center”
that acts in opposition to the VMH “satiety center” (Hoebel and
Teitelbaum, 1962; Hoebel, 1965), and Eliot Stellar summarized
these concepts into the “dual center hypothesis” of feeding
regulation (Stellar, 1954). Subsequent work, however, has revealed
a more complex role for the LHA in control of feeding, as well as
of drinking, physical activity, alertness/arousal and coordination
of sensory stimuli with appropriate output behaviors (Levitt
and Teitelbaum, 1975). Thus, the LHA is not just a “feeding
center” and must be considered in terms of how it coordinates
a spectrum of ingestive and arousal behaviors relevant to energy
balance.
The fact that LHA-lesioned animals imminently died of
starvation and dehydration complicated their use to determine
how the LHA promoted feeding, drinking and other behaviors.
Teitelbaum and Stellar found that rats with LHA lesions could
only be kept alive via force-feeding them liquid nutrients three
times per day (Teitelbaum and Stellar, 1954). This regimen was
a serious toll for Teitelbaum (the last daily treatment was at 2:00
AM!) and he grew desperate for a way to induce the animals to
feed themselves. He recalled another time he’d had to stay up till
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the wee hours dealing with rats, while performing husbandry of a
rat colony during his assistantship:
“. . . I used to stop, munch chocolate bars, and offer the rats some.
I soon discovered that shortly before my break, many rats were
lined up at the front of each cage, all waiting for their treat.
Later, I remembered this when trying to tempt aphagics to eat.
Nevertheless, it was a thrill to see a rat, being kept alive by tube-
feeding, refusing food and water for 2 months postoperatively,
suddenly gobble up bits of chocolate.” (Teitelbaum, 1979)
Thus, Teitelbaum found that LHA-lesioned rats eschewed
normal foods, but could be coaxed to eat sufficient calories
in the form of palatable substances (i.e., evaporated milk,
cookies, milk chocolate but not bittersweet chocolate) to permit
their survival (Teitelbaum and Epstein, 1962). Eventually, the
lesioned rats overcome their aphagia, resume normal feeding
and regain weight. Importantly, this discovery confirmed that
loss of LHA function didn’t negate the ability to feed, but
blunted the motivation to feed, even when food is desperately
needed for survival. Further, it identified the LHA as being
important for feeding drive, though it is not the sole mediator
of motivated ingestion; other neuronal systems exert some
(presumably lesser) drive that can, in time, be sufficient to
mediate survival (Teitelbaum and Epstein, 1962). Intriguingly,
drinking drive remains particularly impaired in LHA-lesioned
animals even after their “recovery”. These seemingly normal
rats do not coordinate physiologic perturbations (e.g., high
salt-intake/dehydration, hunger, altered food valuation) with
appropriately paired drinking or feeding behavior (Teitelbaum
et al., 1969; Marshall and Teitelbaum, 1973; Levitt and
Teitelbaum, 1975). Close observation revealed that drinking
is strictly time-locked with feeding bouts in these rats, “. . .as if
the animal were drinking not to quench its thirst but simply to
wet its mouth. . .perhaps just as a means to wet food and make
it swallow-able” (Teitelbaum et al., 1969). These data, in sum,
revealed that the LHA is crucial for pairing physiologic need, as
conveyed by cues such as dehydration, hunger, etc., with ingestive
behavior.
Anatomists challenged the notion that the “cell-poor” LHA
could itself regulate motivated behaviors, arguing that it was
actually due to lesion or stimulation of the diffuse fiber systems
passing through the LHA. Indeed, coursing through the LHA
are nigro-striatal dopamine (DA) fibers as well as axons of
passage within the medial forebrain bundle (mfb), each of
which terminate in brain centers associated with reward and
motivation (Ungerstedt, 1971). These tracts regulate motivation,
and disruption of the mfb or DA-containing neurons blunts
feeding, drinking and movement behavior, similar to LHA lesions
(Morgane, 1961; Ungerstedt, 1971; Marshall and Teitelbaum,
1973; Szczypka et al., 1999, 2000). Two crucial findings, however,
solidified a specific role for LHA neurons in regulating motivation
relevant to energy balance. First, stimulation of the LHA still
induces motivated feeding even in rats with a severed mfb
(Morgane, 1961). Secondly, treatment with neurotoxins that
selectively ablate LHA cell bodies, but spare axons passing
through the LHA, results in aphagia and adipsia similar to the
original lesions that disrupted both cells and fibers (Grossman
et al., 1978; Dunnett et al., 1985). Thus, these data confirmed
that neurons within the LHA directly modulate motivated
ingestion behaviors. It was subsequently determined that LHA
neurons are anatomically linked with neural systems that
regulate reward and goal-directed behaviors, including direct
projections onto midbrain DA neurons that release DA into the
forebrain (Hernandez and Hoebel, 1988). Taken as a whole, the
classical lesion, stimulation and anatomical studies established
the LHA as a powerful coordinator of the drive to eat, drink
and move. Such methodologies, however, could not define
how LHA neurons coordinate specific status cues from the
body (e.g., need for water vs. food) with appropriate output
behaviors.
CONNECTIVITY AND NEURONAL DIVERSITY IN THE LHA:
IMPLICATIONS FOR ENERGY BALANCE
The strikingly different phenotypes produced by lesion of
the LHA (aphagia, adipsia, weight loss) or periventricular
hypothalamic regions (hyperphagia, obesity) suggests
that these regions differ in neurochemistry and/or their
anatomical engagement of brain systems that regulate behavior.
Hypothalamic nuclei such as the VMH, arcuate nucleus
(ARC), dorsomedial hypothalamus (DMH) and paraventricular
hypothalamic nucleus (PVN) are compact, cell-dense and have
well-defined projection targets throughout the brain. The LHA,
by contrast, encompasses a large swath of tissue over the entire
rostral-caudal extent of the hypothalamus. The sheer expanse
of the LHA, coupled with the fact that it lacks obvious cellular
architecture, complicated anatomical and functional studies. The
LHA lies lateral to the DMH and PVN, and the area just above
and surrounding the fornix is referred to as the perifornical area
of the LHA. Pioneering work by the Swanson group utilized these
anatomical landmarks in combination with neuronal tract tracing
methods to determine the precise connectivity of LHA subregions
with the rest of the brain (Goto et al., 2005; Hahn and Swanson,
2010). While these studies characterized some subregion-specific
projection targets, as a whole they demonstrate that the LHA
projects broadly throughout the forebrain, midbrain and
hindbrain regions, each of which is implicated in distinct facets
of physiologic control; the LHA projections discussed in this
review are shown in Figure 1. The lack of a unified output region,
however, suggests that LHA-mediated regulation of behavior and
energy balance is complex and not homogenous in nature.
The next leap in understanding the LHA’s role in energy
balance was the discovery of its hetero-cellularity, and the
resulting concept that specific populations of LHA neurons
coordinate discrete energy cues and behavioral response. The
full extent of LHA neurons are yet to be characterized, but
three substantial populations of neurons have been described and
can be defined by their expression of a specific neuropeptide:
neurons containing melanin concentrating hormone (MCH),
the orexins/hypocretins (OX) or neurotensin (Nts). Intriguingly,
these neuronal populations are molecularly and spatially distinct,
suggesting that each population may also differ in connectivity
and functional output (Elias et al., 1998; Swanson et al., 2005;
Leinninger et al., 2011).
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FIGURE 1 | Projections Via Which the LHA Coordinates
Behaviors that Impact Energy Balance. The LHA projects densely
into brain regions that modulate motivated behaviors, such as
feeding, drinking, physical activity and addiction to drugs of abuse.
The LHA engages the motivational circuit via direct projections into
the forebrain (NA) and to the midbrain (VTA), which in turn projects
to reward areas of the brain such as the NA, mPFC and Hipp. The
LHA also sends dense projections to hindbrain sites that regulate
arousal/sleep and movement/vigilance, such as the LC and other
sites not shown for sake of clarity. LHA projections onto neurons
within the medulla in turn project via the spinal cord to engage the
autonomic nervous system, thereby modulating heart rate,
respiration, brown adipose tissue/thermogenesis and white adipose
tissue to modulate energy storage. Specific neuronal subsets of the
LHA engage some or all of these sites to coordinate energy cues
and behavioral output that impacts energy balance, as reviewed in
the text. Note that not all projections from the LHA are
represented on this schematic, such as projections to the prefrontal
cortex and hippocampus; though these likely have important roles
in regulating physiology, they are beyond the scope of this review
and thus have not been represented here. Abbreviations: LHA =
lateral hypothalamic area, NA = nucleus accumbens, VTA = ventral
tegmental area, mPFC = medial prefrontal cortex, Hipp =
hippocampus, LC = locus coeruleus, Med = medulla, BAT = brown
adipose tissue, WAT = white adipose tissue. Sagital brain outline
adapted from Paxinos and Franklin (2001).
The development of molecular techniques that enable
site-specific manipulation of genetically-distinct neuronal
populations has allowed the field to probe the roles of MCH, OX
and Nts neurons, and suggests that each of these populations
have roles in regulating energy balance. While there are also
smaller populations of neurons within the LHA expressing
other neuropeptides and neurotransmitters, we will focus on
the emerging and distinct roles of MCH, OX and Nts neurons
in coordinating peripheral energy cues and behaviors, and
their respective contributions to energy balance. In particular
each neuronal population will be considered for its role(s) in
regulation of feeding, drinking and energy expenditure. The
amount of energy expended (and thus weight), is influenced by
the amount of physical activity, sleeping/arousal and thermogenic
outflow, so each of these facets of energy expenditure will be
discussed.
MELANIN CONCENTRATING HORMONE (MCH) NEURONS
DISCOVERY AND CHARACTERIZATION OF MCH SIGNALING
Melanin concentrating hormone (MCH) is a 19 amino acid cyclic
neuropeptide that was first documented in the pituitary of teleost
fish, enabling them to change skin color and blend into their
environment (Kawauchi et al., 1983; Oshima et al., 1986). Soon
after MCH was identified in the brains of rats (Zamir et al.,
1986) and humans (Mouri et al., 1993), where it is primarily
found within neuronal cell bodies of the LHA and a few neurons
in the zona incerta (Bittencourt et al., 1992). Most often these
are solely referred to as MCH neurons, but they also contain
the classical (fast) neurotransmitters GABA or glutamate via
which they can inhibit or excite postsynaptic cells (Elias et al.,
2001; Harthoorn et al., 2005; Jego et al., 2013). Additional sub-
populations of MCH neurons can be differentiated by their co-
expression of nesfatin (Foo et al., 2008) or the neuropeptide
cocaine-amphetamine-regulated transcript (CART; Vrang et al.,
1999; Elias et al., 2001; Brischoux et al., 2002; Cvetkovic et al.,
2004). CART co-expression signifies a distinct MCH population
that projects to forebrain sites involved in behavior modulation,
while non-CART expressing MCH neurons preferentially project
to caudal hindbrain and spinal cord (Brischoux et al., 2002;
Cvetkovic et al., 2004).
MCH acts via neurons expressing the G-protein coupled MCH
Receptor-1 (MCHR-1), which can be coupled to either Gi/o or
Gq proteins (Chambers et al., 1999; Lembo et al., 1999; Saito
et al., 1999; Hawes et al., 2000; Pissios et al., 2003). Human,
primates, cats and dogs (but not rodents) also express a Gq-
coupled MCH Receptor-2 that activates target neurons and may
exert opposite actions to MCHR-1 (An et al., 2001; Rodriguez
et al., 2001; Chee et al., 2014). MCHR-1 is highly expressed
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within neurons of the cerebral cortex, olfactory tubercle, limbic
structures (hippocampus, septum, nucleus of the diagonal band,
bed nucleus of the stria terminalis, amygdala) forebrain (caudate-
putamen, nucleus accumbens (NA) core and shell) and the
ARC (Chee et al., 2013). MCH neurons also project to areas
implicated in regulating feeding, such as the parabrachial nucleus
(Touzani et al., 1993) and PVN (Fekete et al., 2004), but project
sparsely to regions that regulate arousal, such as the dorsal
raphe (DR), ventrolateral periaqueductal gray (VLPAG), locus
coeruleus (LC) and preoptic area (Chambers et al., 1999; Saito
et al., 1999; Borowsky et al., 2002; Chee et al., 2013; Yoon and
Lee, 2013). Though the LHA as a whole densely projects into
the DA-enriched ventral tegmental area (VTA) and regulates
DA-mediated ingestive and locomotor behaviors (Kenny, 2011),
MCH neurons do not regulate the VTA (Chee et al., 2013).
Rather, MCH neurons engage the DA system via projections to
the NA, where MCHR-1 is expressed on dopamine receptor-
1 (D1R) and dopamine receptor-2 (D2R)-expressing medium
spiny neurons (Pissios et al., 2008). MCH acts via a Gi/o-
dependent signaling mechanism to increase K+ current into
medium spiny neurons and reduce their excitability (Sears et al.,
2010). Given that inhibition of NA neurons promotes motivated
behaviors for natural rewards (Taha and Fields, 2006), MCH
signaling via Gi/o-coupled MCHR-1 may inhibit NA neurons
to promote ingestion. Consistent with this model, rodents
lacking either MCH or MCHR-1 exhibit reduced DA-mediated
motivated behaviors (Pissios et al., 2008; Tyhon et al., 2008).
At least one report, however, suggests that MCH and DA act
synergistically to enhance activation of NA shell neurons (Chung
et al., 2009). These conflicting reports of MCH either inhibiting
or promoting the activation of NA neurons could be due to
different Gi/o or Gq coupled signaling via the receptor though
this has yet to be thoroughly explored. MCH neurons also
project to hindbrain regions including the nucleus of the solitary
tract, dorsal motor nucleus of the vagus and ventral medulla
sympathetic premotor areas (Bittencourt et al., 1992; Zheng
et al., 2005b). Hindbrain neurons regulated by MCH project via
the spinal cord or nerves to exert sympathetic tone within the
gastrointestinal, cardiovascular, respiratory and thermoregulatory
systems, including regulation of white and brown adipose tissue
(BAT) to modify energy expenditure (Oldfield et al., 2002,
2007; Zheng et al., 2005b; Stanley et al., 2010; Adler et al.,
2012).
MCH AND FEEDING
Central injection of MCH into the brain increases feeding
in rodents and promotes obesity thus it is considered an
orexigenic neuropeptide (Qu et al., 1996; Rossi et al., 1997;
Glick et al., 2009). Strongly orexigenic neuropeptides such
as neuropeptide Y stimulate appetitive (meal frequency) and
consummatory (meal size) aspects of feeding behavior via the
forebrain and hindbrain (Baird et al., 2006a). By contrast, MCH
only amplifies consumption (size/amount) of normally accepted
substances (water, sucrose, but not bitter quinine), and this
aspect of MCH action is selectively controlled via the forebrain
(Baird et al., 2006b, 2008). MCH treatment, however, does
not preferentially stimulate intake of palatable food or sucrose,
suggesting that MCH regulates general consumption behavior,
but not necessarily hedonic aspects of feeding (Clegg et al., 2002;
Sakamaki et al., 2005). Consistent with this, MCH expression
is increased in hungry animals, including fasted or hyperphagic
leptin-deficient mice (ob/ob), compared to normal controls (Qu
et al., 1996). Similarly, mice that genetically overexpress MCH are
hyperphagic and gain weight (Ludwig et al., 2001). In contrast,
genetically engineered mice that lack MCH eat less, are lean and
exhibit improved metabolic profiles throughout aging (Shimada
et al., 1998; Jeon et al., 2006; Willie et al., 2008). Mice lacking
MCHR-1 are also lean with less body fat than controls, but
this is primarily due to their increased locomotor activity and
energy expenditure. While one might expect decreased feeding in
MCHR-1 deficient mice (due to loss of orexigenic MCH action),
they actually display mild overeating. In this case the modest
hyperphagia may be required to support their increased energy
expenditure, but at any rate, is not sufficient to produce obesity
(Chen et al., 2002; Marsh et al., 2002). Blocking acute action
of MCHR-1 via selective antagonists, however, does suppress
feeding, meal size and weight gain in normal weight and obese
rodents (Borowsky et al., 2002; Kowalski et al., 2004, 2006). These
findings have accordingly spurred interest in development of
brain-permeable MCHR-1 antagonists to reduce food intake and
promote weight loss.
MCH action in the NA shell is particularly important for
increasing the intake of naturally ingested substances. Selective
administration of MCH in the NA increases feeding, but delivery
of an MCHR-1 antagonist in this region inhibits food intake
(Georgescu et al., 2005). Genetic deletion or pharmacologic
antagonism of MCHR-1 also blunts cue-induced responding
for food, suggesting a deficit in learning processes that drive
motivated feeding (Sherwood et al., 2012). MCH neurons sense
nutrient status and accordingly promote the motivation to feed
in order to maintain euglycemia (Kong et al., 2010). Indeed,
activation of MCH neurons promotes intake of sweetened
liquids along with DA output into NA (Domingos et al., 2013).
Thus, MCH neuronal signaling via MCHR-1 in the NA is
sufficient to coordinate energy need and feeding, and may be
a tractable pathway to modulate feeding in energy balance
disorders.
MCH AND DRINKING
Central administration of MCH increases water intake in the
presence or absence of food (Clegg et al., 2003; Sakamaki et al.,
2005). Woods and colleagues demonstrated, however, that MCH
does not specifically promote water intake, and also increases
ingestion of ethanol, sucrose solution and food (Duncan et al.,
2005). Therefore, MCH is likely a general inducer of intake
behavior (eating and drinking). MCH may influence the desire
to drink in order to wet the mouth or via a DA-mediated
reward mechanism, but does not seem to have a specific role in
controlling thirst per se (Watts and Sanchez-Watts, 2007).
MCH AND ENERGY EXPENDITURE
MCH control of physical activity and sympathetic outflow
Based upon the hypophagia of mice lacking MCH, it was
hypothesized that MCH deletion could curb feeding to promote
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weight loss in obesity. The Maratos-Flier group tested this by
genetically deleting MCH in mice that are deficient for leptin,
and hence are hyperphagic and obese. The resulting double
MCH/leptin knock-out mice were leaner than leptin-depleted
controls, but did not exhibit any blunting of feeding. Instead,
the reduced adiposity of MCH/leptin knock-out mice was due
to their increased energy expenditure (Segal-Lieberman et al.,
2003). Indeed, MCH neurons act via polysynaptic connections
to the hindbrain and spinal cord to regulate BAT, the vital tissue
for promoting thermogenesis and basal metabolic rate (Oldfield
et al., 2007). MCH neurons presumably inhibit thermogenic
energy expenditure via this pathway (Bittencourt and Elias, 1998;
Zheng et al., 2005b). By contrast, blockade of MCH signaling
increases BAT mass and thermogenesis and reduces body weight
(Pereira-Da-Silva et al., 2003). Genetic deletion of MCHR-1 in
mice also promotes hyperactivity and increased metabolic rate,
(Marsh et al., 2002; Smith et al., 2005) though some part of this
is mediated via changes in the NA (Smith et al., 2005). Together
these data suggest that the combined increase of thermogenesis
and physical activity supports weight loss and leanness despite
the hyperphagia of these animals. Interestingly, ablation of MCH
neurons in adult obese mice does not decrease their feeding or
body weight (Wu et al., 2012), suggesting that developmental
disruption of MCH neurons is essential for modifying energy
balance.
MCH is also implicated in regulating anxiety and anxiety-
related measures of energy expenditure. MCH may promote
anxiety in humans since MCH levels are lowest during
(presumably positive) social interactions, and this has inspired
interest in MCHR-1 blockade for treating anxiety disorders
(Blouin et al., 2013). Rodents treated with systemic MCHR-1
antagonists or that have a genetic knock-out of MCHR-1 exhibit
decreased anxiety behavior, including improving performance in
forced-swim and social interaction tests (Borowsky et al., 2002;
Georgescu et al., 2005; Smith et al., 2006). Such assays inherently
measure locomotor outcomes, so the improved performance in
these anxiety tests may reflect the general increase in locomotor
activity resulting from MCHR-1 blockade. Other reports using
MCHR-1 antagonists, however, have not confirmed a role for
MCH in anxiety suggesting that more work is needed to
understand the complex role of MCH in this system (Basso et al.,
2006).
MCH and arousal/sleep
Recently central MCH action has also been implicated in
promoting sleeping, and blockade of sleep could promote the
energy expenditure and anxiety effects observed with disrupted
MCH signaling. Central MCH promotes paradoxical (REM)
sleep, while MCHR-1 antagonists reduce it (Verret et al.,
2003; Ahnaou et al., 2008; Lagos et al., 2009; Clement et al.,
2012). Optogenetic activation of MCH neurons also promotes
paradoxical sleep (Jego et al., 2013; Konadhode et al., 2013;
Tsunematsu et al., 2014). In humans MCH levels are maximal
during sleeping (Blouin et al., 2013), and MCH neurons
selectively fire during sleep (Hassani et al., 2009; Sapin et al.,
2010; Clement et al., 2012). Thus, MCH neurons may coordinate
energy savings during periods of sleep, including diminishing
heart rate and motor action/tone via the sympathetic system.
Interestingly, MCH action itself may not be as important as
GABA released from these neurons in promoting sleep (Jego
et al., 2013). By contrast, histamine-producing neurons of the
tuberomammillary nucleus regulate wakefulness, in part via
inhibiting MCH neurons, identifying an important on/off sleep
circuit (Parks et al., 2014).
OREXIN/HYPOCRETIN (OX) NEURONS
DISCOVERY AND CHARACTERIZATION OF OX SIGNALING
In 1998 two groups reported the discovery of two neuropeptides
produced from the same gene product: one group dubbed them
the hypocretins (de Lecea et al., 1998) and the other referred
to them as orexins (Sakurai et al., 1998). We will utilize the
orexin (OX) designation due to its simple abbreviation. The
prepro-OX gene product is proteolytically cleaved into two
similar peptide products, OX-A and OX-B, whose expression
is restricted to neuronal cell bodies in the LHA and to a lesser
extent the DMH (Peyron et al., 1998). OX action is transduced
via two G protein coupled receptors, orexin receptor-1 (OXR-1)
and orexin receptor-2 (OXR-2; Sakurai et al., 1998; Zhu et al.,
2003; Holmqvist et al., 2005). OXR-1 preferentially binds OX-A
and couples to the Gq subclass of G proteins (Sakurai et al.,
1998). OXR-2 binds OX-A and -B with equal affinities and can
couple to Gq, Gs or Gi/o proteins (Martin et al., 2002; Tang
et al., 2008; Ramanjaneya et al., 2009). Strikingly, OX neurons
project broadly throughout the brain (Peyron et al., 1998) and
virtually every brain region contains at least one of the two OX
receptors, suggesting that central OX action controls a wide array
of functions (Trivedi et al., 1998). For example, OX neurons
directly innervate neurons located in reward regions of the
brain (VTA, NA [dopaminergic neurons]), as well as a host of
regions and signals that regulate arousal (LC [noradrenergic
neurons], DR [serotonergic neurons], periaqueductal gray,
lateral dorsal tegmental nucleus, peduncolopontine nucleus,
diagonal band, septal nucleus [cholinergic and other neurons],
tuberomammillary nucleus [histaminergic neurons] and
paraventricular thalamus [multiple populations of neuropeptide-
expressing neurons]) (Peyron et al., 1998; Horvath et al., 1999a).
OX neurons also project into regions that regulate learning
(amygdala, hippocampus), within hypothalamic nuclei that
contribute to energy balance such as the ARC, VMH, DMH,
PVN, and LHA itself, and to caudal hindbrain regions that
regulate autonomic control (reticular formation areas, solitary
nucleus, spinal cord) as well as many others (Peyron et al., 1998;
Chemelli et al., 1999; Date et al., 1999; van den Pol, 1999). Via
projections to the raphe pallidus (Lee et al., 2013) and other
caudal hindbrain sites OX neurons poly-synaptically regulate
BAT (Oldfield et al., 2002), white adipose tissue (WAT), liver
(Stanley et al., 2010; Adler et al., 2012), the pancreas (Wu et al.,
2004) and the gastrointestinal system (Grabauskas and Moises,
2003). The ability of OX neurons to engage multiple neural
systems indicates a powerful role for OX neurons to promote
simultaneous, multifaceted physiological response.
Soon after the discovery of OX followed high impact reports
of its roles in sleep and energy balance (Peyron et al., 2000;
Thannickal et al., 2000; Hara et al., 2001; Yamanaka et al.,
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2003). Subsequently, researchers have begun to approach the
OX system via studying selective OX-mediated circuits, to
determine the contributions of OX action via specific regions
of the brain. Furthermore, several lines of evidence suggest that
there are spatially and electrophysiologically-distinct subsets of
OX neurons, but it remains unclear if subsets preferentially
project to distinct brain regions or how they specifically
contribute to OX-mediated behavior (Swanson et al., 2005;
Harris and Aston-Jones, 2006; Williams et al., 2008; Schöne
et al., 2011). Neurons containing OX are generally defined
as “OX neurons”, but they also co-express insulin-like growth
factor binding protein-3 (Honda et al., 2009), dynorphin (Chou
et al., 2001), the secreted neuronal pentraxin NARP/Nptx2 (Reti
et al., 2002) and glutamate (Rosin et al., 2003; Torrealba et al.,
2003). These appear to be common to all OX neurons, and
thus have not been useful in discriminating between functional
subsets. OX neurons release dynorphin and glutamate from their
synaptic terminals throughout the brain, including at synapses
onto themselves (Li et al., 2002). The glutamatergic output from
OX neurons and OX-mediated suppression of G-protein coupled
inward rectifier (GIRK) channel activity promotes neuronal
excitation (Hoang et al., 2003). OX neurons also autoregulate
via their expression of OXR-2, such that autaptic OX signaling
maintains sustained activation of OX neurons (Yamanaka et al.,
2010). By contrast, dynorphin released from OX neurons onto
themselves, or likely onto other glutamatergic inputs, may
dampen the activation of OX neurons (Li and van den Pol, 2006).
Considering the broad projections of OX neurons throughout
the brain, it is tempting to speculate that their release of
multiple transmitters enables OX neurons to differentially control
targets that express a specific receptor repertoire (e.g., glutamate
receptors but not OXR-1 or OXR-2; Li and van den Pol, 2006).
OX AND FEEDING
Central OX administration acutely promotes feeding (Sakurai
et al., 1998; Ida et al., 1999; Zheng et al., 2005a) though more
modestly compared to other orexigenic neuropeptides (Edwards
et al., 1999). Pharmacological OX potentiates feeding during the
day (when rodents are normally sleeping) but not during dark
cycle (when rodents are awake and do most of their feeding)
(Haynes et al., 1999; Yamanaka et al., 1999; McGregor et al., 2011).
These data collectively support the argument that OX is not a
stimulator of food intake per se, but that it increases arousal and
consequently increases feeding. Simply put, awake animals will
eat. Thus, activating OX neurons or administering OX during
their sleeping period wakes the animal, and the animals spend
some of their awake time eating (España et al., 2002; Inutsuka
et al., 2014). It logically follows that suppressing OX action
when animals are normally awake and eating should reduce their
feeding; indeed central OXR antagonists suppress feeding during
the dark phase (Haynes et al., 2000). Loss of OX neurons results
in either reduced or unchanged food intake, but also increased
sleep, and it’s likely that the reduced waking time inherently limits
the time for ingestion (Zhang et al., 2007; Inutsuka et al., 2014;
Tabuchi et al., 2014).
A growing body of work implicates OX neurons as sensors
of when and if an animal needs to eat. For example, survival in
the wild depends on recognizing cues that signal food availability
(e.g., light, sounds) and to promote locomotor activities to obtain
the food. OX neurons are activated in anticipation of feeding and
couple arousal and feeding behaviors (Akiyama et al., 2004; Mieda
et al., 2004). Accordingly, OX neurons directly sense energy status:
fasting (forced hypoglycemia) increases OX expression (Cai et al.,
1999) and activation of OX neurons, while physiologic increases
in glucose that occur with re-feeding or satiation selectively
inhibit OX neurons (Burdakov et al., 2005; Williams et al., 2008).
Non-essential amino acids also activate OX neurons, even in
high glucose conditions that normally suppress OX activation
(Karnani et al., 2011). Physiologically, amino acid biased sensing
may exist to detect inappropriate increases in nonessential vs.
essential amino acids, such as during starvation-induced muscle
breakdown when amino acids are released into the circulation.
In this case, amino acid-mediated activation of OX neurons
could promote food seeking and intake behavior to resolve the
energy deficit (Karnani et al., 2011). In general calorie-restriction
activates OX neurons (Diano et al., 2003) and OX signaling
is essential to increase locomotor survival behaviors, including
enabling food seeking (Lutter et al., 2008).
OX neurons regulate intake of natural and drug rewards,
at least in part, via direct projections onto VTA DA neurons
(Fadel and Deutch, 2002; Korotkova et al., 2003). OX neurons
are activated during cue-induced feeding (Petrovich et al., 2012;
Cason and Aston-Jones, 2013b), and in turn they activate
VTA DA neurons and promote DA release into the NA and
prefrontal cortex (Vittoz and Berridge, 2006; España et al.,
2010, 2011). OX regulation via this mesolimbic circuit promotes
ingestion of highly salient substances (e.g., high fat diet, drugs
of abuse) but not of comparatively bland chow or aversive
substances (Harris et al., 2005; Thorpe and Kotz, 2005; Borgland
et al., 2009; España et al., 2011; Richardson and Aston-
Jones, 2012; Mahler et al., 2013). Furthermore, OX specifically
promotes motivated response (work) for palatable foods that
is attenuated by OXR antagonists (Choi et al., 2010; Cason
and Aston-Jones, 2013a,b). These reward responses may be
due to OX-induced synaptic plasticity, since OX potentiates
NMDA receptor-mediated excitatory postsynaptic potentials
at VTA DA neurons and promotes behavioral sensitization
(Borgland et al., 2006). Both OX and glutamate release,
however, are required for long-term potentiation of DA signaling
that underlies cue-induced reinstatement (seeking) of rewards.
Given that OX and glutamate are released from the same
neuron, it is proposed that OX potentiates the glutamate-
mediated long-term modifications that are known to underlie
addiction to drugs and natural rewards (Mahler et al., 2013).
By contrast, a decrease in the ratio of OX and dynorohin
signaling suppresses reward response (Muschamp et al., 2014).
Similarly, genetic or pharmacologic disruption of OX signaling
(but presumably leaving other releasable transmitters in OX
neurons intact) inhibits DA release to the NA and operant
responding for drugs, food or sucrose (Abizaid et al., 2006; España
et al., 2010; Sharf et al., 2010; Smith and Aston-Jones, 2012;
Srinivasan et al., 2012). Based on these data it is tempting to
speculate that distinct transmitters released from OX neurons
have different roles in conveying resource need and regulating
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ingestive behavior, but more work is needed to address this
hypothesis.
Circulating factors modulate the activity of OX neurons to
coordinate bodily energy status with the appropriate feeding
behavior. GLP1, for example, activates OX neurons (Acuna-
Goycolea and van den Pol, 2004), as does ghrelin acting
via growth-secretagogue hormone receptors (Lawrence et al.,
2002; Olszewski et al., 2003; Toshinai et al., 2003). Ghrelin
robustly increases feeding via distinct neuronal populations
in the brain including OX neurons (Toshinai et al., 2006).
Ghrelin also promotes phasic activation of VTA DA neurons, but
OXR antagonists blunt these effects and palatable food intake,
indicating a crucial involvement of OX neurons in bridging
ghrelin and DA signaling (Perello et al., 2010; Cone et al.,
2014). Direct ghrelin sensing via OX neurons can thus coordinate
signals of diminished energy reserves to the VTA to promote DA-
mediated food seeking and feeding (Sheng et al., 2014). Similarly,
decreased extracellular glucose levels (as occurs during fasting),
also increase the activation of most OX neurons, presumably
to promote OX-mediated arousal and locomotor processes that
permit food seeking (Yamanaka et al., 2003; Burdakov et al.,
2005). Increases in glucose, as might occur after feeding, initially
suppresses the activity of OX neurons (Sheng et al., 2014), but
most OX neurons adapt so as to maintain excitability and sustain
arousal during energy repletion (Williams et al., 2008).
In contrast, the hormonal signal of energy surfeit, leptin,
causes inhibition of OX neurons and attenuates OX-mediated
food intake (Zhu et al., 2002). The mechanism by which
leptin inhibits OX neurons has been controversial. Reports
suggest that OX neurons express LepRb and thus can be
directly regulated via leptin; these studies used an antiserum
that binds LepRb, but which can also bind the short, non-
signaling form of the LepRb (Håkansson et al., 1999; Horvath
et al., 1999a). Other groups, using electrophysiogic approaches
or knock-in mice that specifically identify LepRb-expressing
neurons, have found that OX neurons do not express LepRb
and are not directly regulated via leptin (Goforth et al.,
2014; Sheng et al., 2014). Instead, separate LepRb-expressing
neurons in the LHA on project to OX neurons (Louis et al.,
2010; Leinninger et al., 2011). Most of these LepRb neurons
contain Neurotensin (Nts) and leptin action via this circuit
can inhibit OX neurons (Goforth et al., 2014; Sheng et al.,
2014). In normal weight animals the synaptic inputs onto OX
neurons are predominantly excitatory, but fasting (e.g., low leptin
tone) increases the excitatory inputs onto OX neurons. Leptin
treatment attenuates the fasting-induced increase in excitatory
tone, presumably restoring (e.g., diminishing) activation of OX
neurons to normal levels (Horvath and Gao, 2005). While it is
tempting to infer that leptin solely acts to oppose OX neurons,
more recent data suggest that leptin and OX act cooperatively
to coordinate energy sensing and behavior in the long term.
For example, OX neurons receive cannabinoid-receptor type
1 (CB1)-expressing synaptic inputs, and in lean mice these
CB1 terminals are primarily glutamatergic (excitatory). In the
obese state the ratio of CB1-expressing inputs is predominantly
GABAergic (inhibitory), but leptin treatment restores excitatory
CB1-terminal bias similar to that of lean mice (Cristino
et al., 2013). At some level leptin and OX signaling may be
synergistic, since disruption of one system also deranges the
other. Indeed, loss of leptin or LepRb promotes obesity and
decreases OX expression compared to normal weight animals
(Cai et al., 2000; Yamanaka et al., 2003). Similarly, chronic OX
overexpression or treatment with OXR-2 agonists improves leptin
sensitivity, and suppresses palatable food intake and weight gain
(Funato et al., 2009). Clearly the control of OX neurons by
nutrient and hormonal cues is complex and intricately tuned to
coordinate energy reserves with appropriate modulation of energy
balance.
OX AND DRINKING
Central OX treatment in rats increases drinking, while water
deprivation increases OX expression (Kunii et al., 1999). Similarly,
pharmacogenetic activation of OX neurons increases water intake
(Inutsuka et al., 2014) but genetic ablation of OX neurons
decreases drinking (as well as feeding, locomotor activity, and
wakefulness) suggesting drive reduction (Zhang et al., 2007;
McGregor et al., 2011; Tabuchi et al., 2014). Mice lacking OX also
drink less sucrose, although their preference for it is unaffected
(Matsuo et al., 2010). Consistent with this, pharmacological
antagonism of OXRs reduces all liquid intake (water, ethanol
and sucrose), suggesting that the OX system promotes general
drinking behavior, regardless of the liquid’s caloric or rewarding
value (Anderson et al., 2014). Activation of OX neurons is linked
with bodily fluid status, such that OX neurons are inactive
during dehydration, but are activated just after drinking/re-
hydration occurs (Watts and Sanchez-Watts, 2007). OX neurons
may, therefore, enhance the motivation to drink when fluid is
available to resolve the water imbalance.
Mechanistically, OX neurons may modulate drinking behavior
via projections to, and excitatory regulation of the subfornical
organ (Kunii et al., 1999; Ono et al., 2008) as well as projections
to the medulla (Zheng et al., 2005a). OX neurons may also
modify drinking behavior via projections into the mesolimbic and
striatal systems, which are implicated in motivational drinking
and drinking secondary to psychiatric dysfunction (psychogenic
polydipsia). Polydipsia is a common complication in psychiatric
patients, particularly in schizophrenics, that promotes excessive
water intake (3–10 L per day) and can lead to water intoxication,
seizures, coma and death (Dundas et al., 2007; Hawken et al.,
2009; Iftene et al., 2013). Two independent reports identified
polymorphisms in OXR-1 that link with psychogenic polydipsia
(Meerabux et al., 2005; Fukunaka et al., 2007). It is unclear
whether these OXR-1 polymorphisms confer gain or loss of
function, though animal studies suggest that increased OX
signaling promotes drinking. However, experimental polydipsia
induced with dopamine receptor-2 antagonists (D2R) is enhanced
via simultaneous antagonism of OXR-1, suggesting that loss of OX
signaling could also promote over-drinking (Milella et al., 2010).
OX AND AROUSAL / ENERGY EXPENDITURE
OX and physical activity
Central OX increases locomotor activity, mainly in the form
of grooming and food seeking behaviors (Ida et al., 1999;
Rodgers et al., 2001; Kiwaki et al., 2004). OX neurons
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are maximally activated during exploration, grooming and
feeding, (Mileykovskiy et al., 2005), and pharmacogenetic-
mediated activation of OX neurons increases locomotor activity
(Inutsuka et al., 2014), linking OX action with locomotor
drive. Inflammatory challenge, however, reduces OX activation
(Becskei et al., 2008; Park et al., 2008) and produces the lethargy
characteristic of acute and chronic illness (Gaykema and Goehler,
2009; Grossberg et al., 2011). OX can regulate somatic movement
(Zhang et al., 2011) but primarily controls motivated locomotor
activity via activation of VTA DA neurons and DA release into the
NA (Narita et al., 2006). Inhibitors of DA signaling thus blunt OX-
mediated locomotor activity (Kotz et al., 2006). Rodents lacking
OX are hypoactive, exhibit less motivated wheel running and
their decreased volitional energy expenditure promotes weight
gain (Anaclet et al., 2009; Tabuchi et al., 2014). Furthermore,
accumulating data suggest that OX expression and/or function is
disrupted and may underlie development of movement disorders
such as Huntington’s Disease and Parkinson’s Disease (Thannickal
et al., 2007; Aziz et al., 2008; Williams et al., 2011; Wienecke et al.,
2012).
While lack of OX action can suppress locomotor activity,
increased OX signaling can promote stress and panic-induced
locomotor activity. OX neurons are activated by the stress related
corticotropin-releasing hormone (CRH), which coordinates
locomotor response during stressful experiences to facilitate
survival, such as the ability to escape predators (Winsky-
Sommerer et al., 2004; Xie et al., 2008; Heydendael et al., 2011).
Similarly, OX also has a role in panic disorder, which is defined
as recurrent anxiety episodes that occur with increased cardio-
respiratory action as part of the sympathetic “fight or flight”
response. Rodent models of panic disorder exhibit increased
activation of OX neurons, and individuals displaying suicidal
behavior also have increased central levels of OX. Limiting OX
tone mitigates panic-induced elevations in locomotor activity
and heart rate similar to antidepressant treatment (Johnson
et al., 2010). Chronic stress and sustained activation of the OX
system could also promote overconsumption of palatable foods
and weight gain (Pankevich et al., 2010). Repeated induction
of panic, however, blunts OX mRNA expression likely via
negative feedback, and may suggest why individuals subjected
to chronic, extreme stress episodes (such as combat veterans
exhibiting post traumatic stress disorder) exhibit low levels of
central OX: the OX system is tapped out (Strawn et al., 2010).
OX action via OXR-1 and OXR-2 exert distinct regulation of
neuronal subtypes that function in stress and arousal, thus
there is hope that targeted OXR-pharmacotherapy may be useful
to treat panic disorder, PTSD and possibly energy balance
disorders (Mieda et al., 2011; Scott et al., 2011; Wu et al.,
2011).
OX and arousal/sleep
The normal function of OX neurons is coordination of
environmental cues and arousal. As such, OX neurons are
preferentially activated just prior to and during active waking, but
are inhibited during sleep (Estabrooke et al., 2001; Eggermann
et al., 2003; Lee et al., 2005). Depletion of OX underlies
human narcolepsy, which is characterized by increased daytime
sleepiness, cataplexy and abrupt transitions from wakefulness
to paradoxical sleep (Nishino et al., 2000; Peyron et al., 2000;
Thannickal et al., 2000). Narcoleptic individuals also have a
higher BMI and increased incidence of metabolic syndrome or
type-2 diabetes, likely due to reduced OX-mediated volitional
movement and energy expenditure (Honda et al., 1986; Schuld
et al., 2000; Nishino et al., 2001; Poli et al., 2009). Clinically,
narcoleptic patients exhibit low OX in the CSF, but normal
levels in plasma, confirming that the disease is due to central
deficit (Dalal et al., 2001). Narcolepsy symptomology is not
apparent until there is physical loss of 80–90% of OX neurons,
at which point OX and other co-expressed proteins are virtually
absent (Crocker et al., 2005). OX neurons are also reduced
after traumatic brain injury, which similarly results in chronic
daytime sleepiness and reduced locomotor activity (Baumann
et al., 2005, 2009; Willie et al., 2012). Additionally, the number
of OX neurons diminishes with age, which may underlie aging-
related lethargy and sleeping disorders (Kessler et al., 2011). It
remains unclear, however, why OX neurons are particularly prone
to injury in disease and aging. Yet, the essential requirement
for the OX system in mediating arousal has been recapitulated
experimentally: loss of OX signaling due to genetic deletion
or ablation of OX neurons causes reduced locomotor activity
and narcoleptic-like behavior in rodents (Chemelli et al., 1999;
Gerashchenko et al., 2001; Hara et al., 2001; Willie et al.,
2003; Beuckmann et al., 2004). Restoration of OX expression
to mice genetically lacking OX ameliorates their narcolepsy (Liu
et al., 2008; Kantor et al., 2013) and the release of OX itself
is sufficient to mediate sleep/wake transition (Carter et al.,
2009). Importantly, the OX system does not impede sleep
per se, but is important in mediating the transitions between
sleeping and waking; mice genetically lacking OX have a low
transition threshold between sleeping and waking, which presents
as an inability to sustain wakefulness and increased amount
of sleeping (Mochizuki et al., 2004; Diniz Behn et al., 2010).
Similarly, optogenetic suppression of OX neurons increases
sleep (Tsunematsu et al., 2011) but optogenetic activation
of OX neurons promotes arousal from sleep (Adamantidis
et al., 2007; Rolls et al., 2011). Indeed, narcolepsy, traumatic
brain injury and aging-related sleeping disorders are similarly
characterized as having inappropriate transitions between waking
and sleeping that manifest as exaggerated sleepiness. Thus,
restoration and/or enhancement of OX action may be clinically
useful in treating narcolepsy, head-trauma and aging-induced
sleeping disorders.
Synaptic inputs onto OX neurons modulate their activation
state, and the neurochemistry of these inputs suggests potential
mechanisms to modify arousal. For example, MCH neurons
within the LHA modulate OX neuronal tone, and may be a
local system for promoting sleep/wake states, respectively (Rao
et al., 2008). Energy status (e.g., fasted/fed) and circadian rhythms
remodel the excitatory input to OX neurons and thus coordinate
energy and time-appropriate arousal (Horvath and Gao, 2005;
Appelbaum et al., 2010). Likewise, the arousal promoting drug
modafinil works by increasing excitatory tone onto OX neurons
similar to long-term potentiation (Rao et al., 2007). Inhibition of
GABAergic or adenosine tone onto OX neurons also promotes
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their activity and increases wake time (Alam et al., 2005; Rai
et al., 2010). OX neurons have GABAA receptors and GABAB
receptors (Sergeeva et al., 2005; Xie et al., 2006), via which GABA
may inhibit OX neurons and promote the transition to the sleep
state (Alam et al., 2005; Matsuki et al., 2009). Indeed, agonists
of GABAA receptors such as benzodiazepines and anesthetics
inhibit OX neurons and their arousal/vigilance-mediated effects
(Sergeeva et al., 2005). GABAergic regulation of OX neurons and
OXR antagonists are accordingly of great interest, since these may
be useful pharmacologic strategies to treat insomnia (Brisbare-
Roch et al., 2007).
OX neurons exert regulation of arousal via projections to
specific target regions of the brain, including the LC, the
dorsal raphe (DR) the tuberonmamillary nucleus (TMN) and
via regulation of LHA MCH neurons. The LC receives dense
innervation from OX neurons, and OX increases activation of LC
neurons, arousal and locomotor behaviors (Hagan et al., 1999;
Horvath et al., 1999b; Bourgin et al., 2000; Walling et al., 2004).
OX neurons mediate sleep to wake transition via activation of LC
noradrenergic neurons (Chen et al., 2008; Carter et al., 2012),
and restoration of OXR-1 signaling in the LC of narcoleptic
rodents rescues their ability to sustain wakefulness (Hasegawa
et al., 2014). Restoration of OX action in the serotonergic DR, by
contrast, suppresses the cataplexy (freezing) of narcoleptic models
(Hasegawa et al., 2014). OX also activates histaminergic neurons
of the TMN (Bayer et al., 2001; Eriksson et al., 2001; Schone et al.,
2012). Histamine mediates at least some portion of OX effects on
wakefulness, as OX action is blunted during histamine receptor
blockade (Huang et al., 2001). Restoration of OXR-2 signaling
selectively in TMN, however, rescues arousal function, suggesting
an important OX and histamine-integrated circuit (Mochizuki
et al., 2011). Collectively these data suggest that OX action via
specialized centers of the brain, and their distinct expression of
OXR-1 and/or OXR-2 mediate different aspects of alertness and
motor control.
OX and sympathetic control
OX neurons are referred to as “command neurons” because
they project to brain sites that simultaneously control feeding,
locomotor activity (hypothalamus, VTA) and arousal (LC, DR,
TMN), as well as to sympathetic response centers that are
necessary to support such behaviors (Oldfield et al., 2007).
OX increases sympathetic outflow, therefore increasing blood
pressure, heart rate, respiration and body temperature in rats,
via OX action in caudal medullary sites such as dorsal vagal
complex and raphe pallidus (Shirasaka et al., 1999; Wang et al.,
2001; Zheng et al., 2005a; Johnson et al., 2012). OX neurons
activate sympathetic premotor neurons in the raphe pallidus that
accordingly modify synaptic tone onto BAT; gain or loss of action
via this OX-controlled polysynaptic circuit can thus increase
or diminish thermogenesis as required to match energy needs
(Tupone et al., 2011). Loss of OX command neurons, however,
decreases body temperature and stress-induced thermogenic
response (Zhang et al., 2010; Sellayah et al., 2011). OX neurons
also exert sympathetic control of muscle to couple energy levels
with required physical response (Shiuchi et al., 2009).
NEUROTENSIN (Nts) NEURONS
DISCOVERY AND CHARACTERIZATION OF Nts SIGNALING
In 1973 Carraway and Leeman isolated a 13 amino acid peptide
from bovine hypothalamus. Upon finding that intravenous Nts
injection dilated blood vessels, lowered blood pressure and
caused cyanosis in rats they coined this peptide Nts to reflect
its pressor function (Carraway and Leeman, 1973). Most Nts
(approximately 85%) is expressed within the intestine, but 10%
of bodily Nts expression is within the brain. Nts is also found
within the plasma (likely released from the intestine), but
degrades rapidly so circulating Nts is unlikely to reach distant
tissues, such as the brain, in an intact state (Lee et al., 1986).
Nts is enriched in synaptosomes within the brain (Uhl and
Snyder, 1977; Uhl et al., 1977) and is released after neuronal
depolarization via a calcium dependent mechanism, signifying
that Nts is a peptide neurotransmitter in the brain (Iversen et al.,
1978). Nts in the brain is also rapidly degraded by membrane-
bound angiotensin converting enzyme, proline endopeptidase
and prohormone convertases-1 and -2, suggesting that it mediates
short-acting signal transduction that is quickly inactivated
(Checler et al., 1983; McDermott et al., 1986; Rovere et al.,
1996a,b). Using in situ hybridization or radioimmunolabeling
Nts was identified throughout the nervous system, including
within the spinal cord, hindbrain (nucleus of solitary tract,
LC, parabrachial nucleus), midbrain (periaqueductal gray, VTA,
substantia nigra) limbic system (amygdala, hippocampus),
forebrain (caudate putamen, NA), thalamus, and within the
hypothalamus, particularly the preoptic area, PVN and the LHA
(Kahn et al., 1982; Uhl, 1982; Roberts et al., 1984; Zahm,
1987; Allen and Cechetto, 1995). Immunohistochemical detection
of Nts, however, requires treating rodents with colchicine, an
anterograde transport inhibitor that leads to accumulation of
proteins within the cell body, but which is inherently toxic
and prevents study of these neurons in normal physiologic
context (Kahn et al., 1982; Kalivas et al., 1982; Uhl, 1982;
Bean et al., 1989). This technical limitation impeded study of
Nts neurons, which is why there is comparatively less known
about the Nts neurons in the LHA compared to MCH and OX
neurons. It is important to note that Nts-expressing neurons
are not restricted to the LHA. Yet, given the large population
of LHA Nts neurons (Watts et al., 1999; Leinninger et al.,
2011) and emerging reports of their specific roles in energy
balance (Watts and Sanchez-Watts, 2007; Leinninger et al., 2011;
Cui et al., 2012; Kempadoo et al., 2013; Opland et al., 2013),
it is worth considering how Nts mediates behavior and body
weight.
Nts binds to the G-protein coupled receptors, neurotensin
receptor-1 (NtsR-1) and NtsR-2, (Mazella et al., 1985; Wang
and Wu, 1996). A third receptor, neurotensin receptor-3 (NtsR-
3, also called sortillin) is a single transmembrane receptor that
binds Nts, but does not specifically transduce Nts signals (Mazella
et al., 1998). NtsR-1 has high affinity for Nts, is predominantly
expressed on neurons and is generally coupled to Gq proteins
(Tanaka et al., 1990; Hermans et al., 1992). NtsR-2 exhibits
low affinity Nts binding, is antagonized by the antihistamine
levocabastine, may be expressed in neurons and astrocytes and
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can couple to Gq proteins. (Kitabgi et al., 1987; Mazella et al.,
1996; Nouel et al., 1997, 1999; Yamauchi et al., 2007). There is
also evidence that Nts binding to NtsR-2 is non-excitatory and can
suppress NtsR-1 mediated activation, possibly via a Gi/o-coupled
mechanism (Yamada et al., 1998; Hwang et al., 2010). Nts binding
assays in the rodent and human brain suggest that NtsRs are
expressed within the cingulate cortex, midbrain (periaqueductal
gray, DR, VTA, SN), subiculum and in the hindbrain (dorsal
motor nucleus of the vagus, nucleus of the solitary tract, raphe
pallidus, laterodorsal and pedunculopontine tegmental nuclei)
(Kessler et al., 1987; Moyse et al., 1987; Najimi et al., 2014). NtsR-
1 and NtsR-2 also bind xenin, a neuropeptide that is structurally
similar to Nts but which is derived from a different gene product
(Pozza et al., 1988; Feurle, 1998).
Nts specifically promotes activation of NtsR-expressing
neurons in the prefrontal cortex, VLPAG, substantia nigra and in
VTA DA neurons (Behbehani et al., 1987; Audinat et al., 1989;
Seutin et al., 1989). In general, Nts action via NtsRs induces a
non-selective cation current to promote neuronal depolarization
(Lu et al., 2009). Additionally, on DA neurons Nts opposes
the inhibitory effects of D2R signaling, thus Nts acts via dual
mechanisms to promote the activation of DA neurons (Shi
and Bunney, 1991; Farkas et al., 1997; Werkman et al., 2000;
Legault et al., 2002). Indeed, within the VTA Nts-containing
axon terminals are primarily apposed with DA neurons (Woulfe
and Beaudet, 1992) and Nts acts via the VTA to promote
DA release into the NA and modify reward behavior (Blaha
et al., 1990; Singh et al., 1997). Both NtsR-1 and NtsR-2 are
implicated in regulating DA neurons (Szigethy and Beaudet,
1989; Nalivaiko et al., 1998; Sotty et al., 1998), but treatment
with NtsR-1-sepecific antagonists blocks Nts-mediated DA release
from midbrain neurons (Gully et al., 1993; Brouard et al., 1994).
Collectively these data suggest that NtsR-1 is the predominant
receptor isoform in neurotensin-mediated regulation of VTA DA
neurons.
The development of mice that express cre recombinase in Nts
neurons (NtsCre mice) permitted the facile identification of Nts
neurons throughout the brain, including a large population of
Nts neurons within the LHA (Leinninger et al., 2011). These
NtsCre mice, when bred onto a cre-mediated green fluorescent
reporter line, identify LHA Nts neurons that are distinct from
adjacent neurons expressing MCH or OX, similar to previous
reports that identified Nts, OX and MCH via in situ hybridization
or colchicine-mediated immunostaining (Watts and Sanchez-
Watts, 2007; Leinninger et al., 2011; Laque et al., 2013). LHA
Nts neurons, however, are not a homogenous population; there
are subpopulations of Nts-containing neurons within the LHA
with distinct molecular signatures, though these have yet to
be fully characterized. Some LHA Nts neurons co-express the
long form of the LepRb and are activated by leptin (Leinninger
et al., 2011) and some of these neurons also co-express the
inhibitory neuropeptide galanin and/or melanocortin-4 receptor
(Cui et al., 2012; Laque et al., 2013). Other subpopulations of
Nts neurons contain CRH (Watts and Sanchez-Watts, 2007) or
MCHR-1 (Chee et al., 2013). Further, some LHA Nts neurons
co-express the classical neurotransmitters GABA or glutamate
(Leinninger et al., 2011; Kempadoo et al., 2013). As a whole,
LHA Nts neurons project densely within the LHA to OX neurons
and also to the VTA, via which they likely regulate DA neurons.
Indeed, activation of LHA Nts neurons potentiates the activation
of VTA DA neurons via an NtsR1-dependent mechanism and
mice self-stimulate LHA Nts neurons, presumably because it
is rewarding (Kempadoo et al., 2013). LHA Nts neurons also
regulate the activity of OX neurons via mechanisms that remain
to be determined (Leinninger et al., 2011; Furutani et al., 2013;
Goforth et al., 2014). Thus, LHA Nts neurons exert control of OX
neurons and VTA DA neurons that could (as established above)
modulate feeding, drinking and locomotor activity. While the
precise roles of LHA Nts neurons in these physiologic behaviors
have yet to be fully elucidated, there is a large literature to suggest
that central Nts can indeed modify behaviors relevant to energy
balance, as reviewed below.
Nts AND FEEDING
Central Nts modestly decreases food intake in satiated and food-
deprived rodents, in part via actions in the substantia nigra
and VTA (Stanley et al., 1983; Hawkins, 1986a,b; Vaughn et al.,
1990; Boules et al., 2000). Administration of Nts into the LHA
or ventral striatum, however, does not alter feeding, suggesting
either a lack of NtsRs in these regions or that they regulate other
aspects of behavior (Hawkins, 1986b; Hawkins et al., 1986). Loss
of Nts expression might therefore be expected to promote feeding
and exacerbate weight gain. Indeed hyperphagic, obese rodents
have reduced Nts expression in the brain, including within the
hypothalamus, that may contribute to the disease state (Sheppard
et al., 1985; Beck et al., 1989, 1990, 1992; Williams et al., 1991;
Wilding et al., 1993).
Nts neurons are regulated by the anorectic hormone leptin,
suggesting coordinated roles of Nts and leptin to modify feeding
and body weight. Chronic leptin treatment decreases food intake
and body weight as expected, and also decreases Nts expression
within the LHA (Sahu, 1998; Richy et al., 2000). By contrast,
acute leptin treatment of hypothalamic-derived cell lines increases
Nts expression (Cui et al., 2006). NtsR-1 is the essential receptor
isoform for Nts-mediated suppression of feeding (Remaury
et al., 2002; Feifel et al., 2010). Nts potentiates leptin-mediated
inhibition of feeding via NtsR-1 (Beck et al., 1998; Sahu et al.,
2001) but mice deficient in NtsR-1 have an impaired anorectic
response to leptin, confirming that leptin and Nts/NtsR-1
synergistically modify feeding (Kim et al., 2008). Intriguingly, the
leptin/NtsR-1 system may have more impact in regulating non-
homeostatic feeding: while mice lacking NtsR1 exhibit normal
chow intake, they over consume palatable, high-fat diet or a
sucrose solution that promotes obesity (Opland et al., 2013).
The LHA is the site of leptin and Nts synergy: approximately
30% of Nts neurons co-express LepRb, the co-expressing neurons
are exclusively found within the LHA, and represent the only
Nts neurons in the brain that are directly activated by leptin.
Deletion of LepRb specifically from LHA Nts-LepRb neurons
promotes mild hyperphagia and obesity in mice (Leinninger
et al., 2011). Furthermore, intact NtsR-1 expression is required
for LHA Nts-LepRb neurons to restrain feeding, indicating the
functional integration of leptin and Nts/NtsR-1 action (Opland
et al., 2013). In this regard, stimulating NtsR-1 neurons (similar
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to leptin-mediated Nts release from LHA Nts-LepRb neurons)
may be useful to suppress feeding and body weight. Indeed, brain
permeable NtsR-1-specific agonists decrease feeding and body
weight in normal mice, as well as in leptin-deficient obese mice,
suggesting that Nts action via NtsR-1 may be useful in treating
obesity (Feifel et al., 2010).
LHA Nts neurons, including Nts-LepRb neurons, likely exert
some regulation of feeding via their projections to the VTA
(Leinninger et al., 2011; Opland et al., 2013). Nts activates VTA
neurons, promotes reinforcement (Glimcher et al., 1984) and rats
will self administer Nts as if it is rewarding (Glimcher et al.,
1987). Similarly, activation of LHA Nts neurons promotes reward
responding (Kempadoo et al., 2013) though it is unclear how this
modifies feeding. Give that Nts-mediated anorexia is enhanced
by co-administration with DA agonists (Hawkins et al., 1986),
activation of LHA Nts neurons may stimulate VTA DA neurons
to suppress feeding. LHA Nts neurons may also project to the
parabrachial nucleus (Moga et al., 1990), and it is possible that
Nts contributes to anorectic drive via this brain region (Carter
et al., 2013). Additionally, some LHA Nts neurons co-express
MC4R and LepRb (but not OX or MCH) and may be regulated
via melanocortins to modulate feeding (Cui et al., 2012).
Nts AND DRINKING
Water deprivation or osmotic stimulation specifically increases
Nts expression in the LHA (Watts, 1992; Watts et al., 1999).
Sensing of water deficit occurs, at least in part, via the
subpopulation of LHA Nts neurons that co-express CRH (Watts
et al., 1995). There are a modest number of CRH-containing
neurons in the LHA of rats, most of which co-express Nts, but
overall these CRH-Nts neurons represent a minority of the total
LHA Nts neurons (Watts and Sanchez-Watts, 2007). Interestingly,
water deprivation likely increases the activity of LHA Nts neurons
while OX neuronal activity is only increased after drinking
(Watts and Sanchez-Watts, 2007). It is thus tempting to speculate
that Nts neurons signal the degree of “thirst” while activation
of OX neurons drives water intake, if water is available. This
could explain why rodents with ad libitum water will drink
after central Nts treatment [here the Nts-signaled “thirst” can
be instantly resolved by drinking] (Stanley et al., 1983; Quirk
et al., 1988; Baker et al., 1989; Sandoval and Kulkosky, 1992)
or after direct activation of OX neurons that promotes intake
behavior (Inutsuka et al., 2014). Moreover, Nts may promote
water sensing via stimulating stretch-activated cation channels
that mediate osmoreception and sodium detection, thereby
potentiating hypertonic stimulation of cells with these channels
(Chakfe and Bourque, 2000). Nts may also have a general role in
inhibiting intake of “rewarding” liquids such as ethanol (Lee et al.,
2010, 2011), sucrose (Opland et al., 2013) or thirst-induced water
intake, which may be itself be pleasurable after dehydration.
Nts AND ENERGY EXPENDITURE
Nts and physical activity
Nts exerts brain site-specific control of locomotor activity. Nts
in the NA (which is not directly regulated by LHA Nts neurons)
suppresses locomotor activity (Ervin et al., 1981; Kalivas et al.,
1982; Nemeroff et al., 1982; Jolicoeur et al., 1985; Skoog et al.,
1986). By contrast, Nts treatment in the VTA promotes locomotor
activity along with DA output into NA and olfactory tubercle
(Kalivas et al., 1981, 1983, 1985a; Kalivas and Duffy, 1990). Given
that LHA Nts neurons project to the VTA, Nts released from these
neurons may similarly promote DA-mediated physical activity
(Leinninger et al., 2011; Kempadoo et al., 2013; Opland et al.,
2013). NtsR-1 is an essential mediator of Nts-mediated locomotor
activity in the VTA (Steinberg et al., 1994). Chronic Nts
administration into the VTA causes long-lasting sensitization and
progressively increased locomotor activity even after treatment is
suspended, suggesting that sustained, endogenous release of Nts
remodels VTA circuits to modulate locomotor output (Kalivas
and Taylor, 1985; Elliott and Nemeroff, 1986). Since LHA Nts
neurons project to and can activate NtsR1-expressing DA neurons
(Leinninger et al., 2011; Opland et al., 2013), they may promote
locomotor activity via NtsR1-dependent actions in the VTA.
Indeed, silencing the 30% of LHA Nts neurons that co-express
LepRb, and presumably blunting Nts release to the VTA, reduces
locomotor activity and disrupts DA signaling (Leinninger et al.,
2011). Functionally, Nts action in the VTA may also exert
antidepressant effects, as it increases forced swim efforts even
at sub-threshold doses that do not promote general locomotor
increase (Cervo et al., 1992). Stress increases Nts in the VTA,
perhaps to potentiate adaptive locomotor behaviors needed for
survival (Deutch et al., 1987; Wachi et al., 1987). Central or
systemic Nts, however, diminishes locomotor effects, suggesting
that Nts actions in the NA outweigh those via the VTA (Kalivas
et al., 1983; Elliott et al., 1986; Vadnie et al., 2014). The cellular
localization of NtsRs likely accounts for the differential control of
locomotor activity via NA and VTA neurons. VTA DA neurons
express NtsRs at the dendrites and soma, so Nts action via
stimulatory NtsRs promotes activation of DA neurons and release
of DA into the NA that induces locomotor activity. By contrast,
Nts injected directly into NA acts via NtsRs on the dendrites
and soma of GABAergic spiny neurons (Herve et al., 1986).
Increasing Nts action via the NA may be useful to suppress the
excessive locomotor effects in schizophrenia, similar to the effects
of antipsychotics (Binder et al., 2001). LHA Nts neurons, however,
do not project into the ventral or dorsal striatum, and thus likely
promote locomotor activity via projections to, and regulation of
VTA DA neurons (Leinninger et al., 2011; Opland et al., 2013).
LHA Nts neurons additionally project within the LHA and
modulate OX neurons (Leinninger et al., 2011; Goforth et al.,
2014), which also regulate ambulatory activity. Some Nts neurons
in the LHA are activated by inflammatory signals, but adjacent OX
neurons are inhibited in these conditions, suggesting differential
control of these neuronal populations (Grossberg et al., 2011).
LHA Nts neurons project onto and inhibit OX neurons (Goforth
et al., 2014), thus inflammation or illness-mediated activation of
Nts neurons can presumably suppress the activity of OX neurons
and decrease locomotor activity during these states (Grossberg
et al., 2011; Leinninger et al., 2011). Similarly, loss of action via
LHA Nts-LepRb neurons decreases locomotor activity and energy
expenditure in mice that promotes obesity (Leinninger et al.,
2011), and some portion of these effects are likely mediated via
regulation of OX neurons (Leinninger et al., 2011; Opland et al.,
2013).
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Nts and arousal/sleep
To date there are no direct reports concerning the role of LHA
Nts neurons in arousal. Burdakov described a large population
of non-MCH, non-OX GABAergic neurons in the LHA that are
spontaneously active during waking and sleeping periods, and it
is possible that these are Nts neurons (Karnani et al., 2013). There
were four subtypes of these uncharacterized GABAergic neurons,
each of which exhibited distinct electrophysiogic properties
(firing rate/response). Similarly, LHA Nts neurons are genetically
heterogeneous (e.g., vary in expression of LepRb, galanin,
melanocortin-4 receptor, CRH, as discussed above), and many
of them are GABAergic (Leinninger et al., 2009), so it is possible
that these electrophysiologically distinct populations are in fact
subpopulations of LHA Nts neurons (Hassani et al., 2010; Sapin
et al., 2010; Karnani et al., 2013). Central administration of
Nts promotes alertness and prolongs latency to sleep stages,
suggesting that LHA Nts neurons could play a role in sustained
arousal (Castel et al., 1989).
Nts and sympathetic control
Central Nts increases analgesia (Clineschmidt et al., 1979; Osbahr
et al., 1981), possibly via LHA Nts neurons that project to and
activate neurons in the VLPAG (Shipley et al., 1987). Inhibitors of
Nts degradation also enhance Nts-mediated analgesia, (Vincent
et al., 1997) and both NtsR-1 and NtsR-2 contribute to Nts-
mediated analgesia (Dubuc et al., 1999; Pettibone et al., 2002;
Remaury et al., 2002). Site-specific Nts agonists may have
potential use as analgesics, and would lack the addictive properties
of opioid-based drugs that are currently used for pain treatment
(Kleczkowska and Lipkowski, 2013). Nts also lowers body
temperature (Bissette et al., 1976, 1982; Nemeroff et al., 1977;
Martin et al., 1980). Many non-OX LHA neurons project to the
raphe pallidus and are poised to regulate somatic and sympathetic
systems (e.g., BAT); these could be Nts neurons (Tupone et al.,
2011). Nts fibers have also been detected in the solitary nucleus
and caudal medulla, and are accordingly poised to regulate cardiac
and vagal preganglionic motor neurons (Behbehani and Pert,
1984; Higgins et al., 1984; Griffiths et al., 1986; Behbehani et al.,
1987, 1988; Fang et al., 1987; Kawai et al., 1988). Nts may also act
via the VTA to promote hypothermia (Kalivas et al., 1985b; Popp
et al., 2007). Nts–meditated analgesia and suppression of body
temperature may support physiologic alertness and contribute to
the anxiolytic effects of Nts (Hou et al., 2011). LHA Nts neurons
are specifically responsive to stress (Seta et al., 2001) so it is
possible that Nts released to the VLPAG, caudal medulla, and
VTA may collectively promote analgesia, autonomic outflow and
locomotor activity to support survival, such as fight or flight
behaviors, but this has yet remains to be experimentally verified.
SUMMARY AND IMPLICATIONS: THE LHA IS “TUNED” TO
COORDINATE ENERGY CUES AND BEHAVIOR
The LHA has now long-been regarded as an essential brain
region for promoting feeding, drinking and energy expenditure
behaviors that inherently modify energy balance and weight.
The LHA, however, appears to coordinate a diverse array of
peripheral cues that range in nature from hormones, nutrient
levels, osmolality, light and sound as well as neurotransmitter
inputs from other brain centers. From an anatomical perspective,
the large LHA contains multiple populations of neurons that
project to virtually every region of the brain. Thus, the
LHA seemingly manages the daunting task of receiving and
interpreting cues from the body, and then matching appropriate
behaviors and physiologic regulation to each cue via a broad
network of neuronal regulation. The discovery of neuropeptide-
specific populations within the LHA has catapulted the field’s
understanding of how the LHA can manage such a formidable
task: via specialized, cue-sensitive neurons that mediate actions
via distinct neuronal projections. While the characterizations of
MCH, OX and Nts neurons have begun to illuminate specialized
functions of each population, these studies are only the tip of
the iceberg, so to speak. As we drill down to understanding the
precise molecular signature of OX, MCH and Nts neurons we
are likely to identify even further specialized subpopulations of
these neurons. It is tempting to speculate that, perhaps, specified
subpopulations mediate the response to particular physiologic
cues and match behavior to restore energy balance. Such parceling
would enable targeting of therapies to either amplify or inhibit
feeding, drinking, physical activity, antinociception and arousal,
and accordingly ameliorate a number of health conditions. In
reality, it is unlikely that the neuronal signatures will be easily
identifiable or so conveniently specialized, as neuronal systems
tend to overlap in function and projections. Indeed, the fact
that MCH, OX and Nts neurons are neuropeptide-distinct but
project to and regulate similar neuronal targets and sites within
the brains speaks to this fact. Even so, MCH, OX and Nts
neurons do contribute differential physiologic regulation. MCH
neurons largely regulate physical activity and energy expenditure
but do not contribute as abundantly to regulation of arousal. OX
neurons are the predominant LHA neuronal mediators of arousal,
and must integrally regulate feeding, activity and sympathetic
outflow to support alertness. Inherently, both MCH and OX
neurons may increase feeding to support energy-consuming
physical activity and alertness. In contrast, the few studies to date
suggest that LHA Nts neurons are required to restrain feeding
and promote physical activity. Thus overall, there are likely
to be distinct physiologic contributions of these neuropeptide-
specific populations that permit the LHA’s impressive regulation
of motivation, energy balance and survival. Just as the discovery
of neuronal heterogeneity in the LHA prompted the idea of
functional divergence, utilization of reagents to selectively identify
and modulate MCH, OX and Nts neurons will reveal their
selective circuitry and functional contributions to energy balance.
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